Evidence map›Paper›PMID 42015780›Full record

Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026

Efficacy and safety of Jiawei Simiaoyongan granules in the treatment of non-infectious anterior uveitis: a randomized open-label trial.

Sun Wu, Chu Liqun, Zhou Wanyu, Shi Hang, Chen Shuiling, Liang Yu, W U Jianguo, Wei Dong, Liu Yushen, Zhang Qi

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sun WuDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.
Chu LiqunDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.
Zhou WanyuDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.
Shi HangDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.
Chen ShuilingDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.
Liang YuDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.
W U JianguoDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.
Wei DongDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.
Liu YushenDepartment of Encephalopathy,Dongzhimen Hospital, Beijing University of Chinese Medicine,Beijing100007,China.
Zhang QiDepartment of Ophthalmology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing100091,China.

Funding

Beijing Natural Science Foundation 7244501Capital Health Development Research Project: Research on the Treatment of Non-infectious Uveitis Based on Disease-Syndrome Combination" 2022-2-4174Hospital Capability Enhancement Project of Xiyuan Hospital, China Academy of Chinese Medical Sciences: a Randomized Controlled Trial of Acupuncture with Huoxue Tongluo Therapy for Neovascular Age-related Macular Degeneration XYZX0202-10Study on the Mechanism of Liangxue Sanjie Decoction in Treating Subretinal Fibrosis Secondary to Neovascular Age-related Macular Degeneration Based on miR155-mediated Autophagy" 82405489
6 · The paper itself

Abstract

objectiveTo observe the clinical efficacy and safety of Chinese herbal medicine Jiawei Simiao Yongan granules (, JWSMYAG) in the treatment of non-infectious anterior uveitis (NIAU).

methodsWe conducted a single-center, randomized, open-labeled clinical trial in adults with NIAU. Patients received standard treatment or a combination of JWSMYAG (twice daily) for three months, with a 3-month withdrawal period for observation. The primary endpoint was the recurrence rate within six months.

resultsA total of 98 patients were included in the intention-to-treat analysis, including 49 patients in the Traditional Chinese Medicine (TCM) group and 49 patients in the control group. Compared with the control group, the number of relapses was significantly lower in the TCM group [24.5%

conclusionJWSMYAG can reduce the recurrence rate of NIAU, alleviate ocular pain, insomnia, and bitter taste symptoms in patients with NIAU, and have a favorable safety profile.

Indexed as

Drugs, Chinese HerbalUveitis, AnteriorAdultAgedFemaleHumansMaleMiddle AgedTreatment OutcomeYoung AdultDrugs, Chinese HerbalJiawei Simiaoyongan granulesnon-infectious anterior uveitisrandomized controlled studyrecurrence ratesafety

Identifiers

PMID42015780
PMCPMC13146387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.